INTRODUCTION
As the field of hematopoietic cell transplantation (HCT) matures and the number of long-term survivors grows, 1 it is critical to acknowledge and understand the significant symptoms and functional deficits and late effects that are caused by the treatment itself. Quality of life is a dynamic, multidimensional construct that is assessed by patient self-report. Numerous patient-reported outcome (PRO) measures exist for the purpose of assessing symptoms and function. In fact, the multitude of measures now available represents a challenge to the field: a variety of measures address the same concept or have 1 or more overlapping domains, the quality widely varies, the length and complexity are excessive, and there is difficulty in comparing findings across studies and conditions. 2 Both autologous HCT (in which the patient's own cells are re-infused) and allogeneic HCT (in which cells come from a donor) are intensive procedures. HCT failure with a relapse of the original disease is a devastating outcome for either HCT methodology, but many patients can be treated again with a second transplant or novel therapeutic agents. Because of the immunological disparity between patient and donor cells, patients undergoing allogeneic HCT are also at risk for graft-versus-host disease (GVHD), a multisystem disorder requiring high doses of immunosuppressants for therapy and well recognized to be associated with significant deficits in symptoms and function. For patients who do not relapse or develop GVHD, other late effects develop at a rate higher than that in the general population; these effects include endocrine problems (eg, diabetes and hypothyroidism), cardiac problems (eg, metabolic syndrome), and subsequent malignancies. 3 These conditions can all result in deficits in symptoms and function after HCT, which for some patients may be long-lasting; however, a large proportion of patients will achieve their baseline symptoms and function 1 to 2 years after HCT. 4 Factors that have previously been associated with worse symptoms and function include age, sex, and certain characteristics of the transplant procedures (eg, chemoradiotherapy and donor type), which increase the risk for GVHD. 5, 6 Both negative and positive impacts on a patient's psychological well-being have been described in the post-HCT setting. 7 Our group recently published a review and opinion piece 8 calling for harmonization in the use of PRO measures in the setting of HCT. That article provides several general recommendations, including the desirability of developing a standard core set of domains of interest and using a free and easily accessible system that is versatile and has a low respondent burden.
The Patient-Reported Outcomes Measurement Information System (PROMIS) is a set of personcentered measures housed under the HealthMeasures platform. Developed in 2004, PROMIS uses modern psychometric theory to standardize PRO assessment for use in both clinical research and health care delivery settings. Extensive psychometric testing has since been performed in large community and clinical samples (including cancer patients) to validate PROMIS item banks. [9] [10] [11] A key feature of PROMIS is that all scores are generic (not diseasespecific) and thus are applicable to use in the setting of HCT, where multiple different diseases may be represented in the patient population. PROMIS offers numerous benefits for addressing current symptom and functional measurement challenges: it is free to use, is easily accessible (via multiple electronic and paper-based platforms), and is flexible. All PROMIS scores use a standardized T-score metric against normative data for the US general population. All PROMIS measures within a domain can be scored and compared on the same T-score metric, regardless of the number or items administered. This allows comparisons across studies and diseasespecific populations that may use different PROMIS measures. Legacy measures, including the 36-Item Short Form Health Survey (SF-36), have been linked to specific PROMIS domains with the PROsetta Stone project, and this allows all measures to be used and interpreted within the same T-score scale. 12 In addition, most PROMIS measures can be delivered as static short forms or through computer adaptive testing (CAT), 13 an innovation that can decrease the responder burden by measuring symptoms and function with fewer questions because it tailors subsequent questions according to a patient's previous answers. PROMIS CAT has been developed with data elements that will allow ease of integration with the electronic medical record. 2 Finally, PROMIS measures have been validated in multiple languages. 14 Despite potential logistic and scientific benefits, there is limited experience with the PROMIS measures in HCT, [15] [16] [17] and only a single study has investigated correlations between PROMIS and other PRO measures in this population. 16 Therefore, the aim of this study was to determine whether the PROMIS measures perform well in the assessment of general symptoms and function in the post-HCT setting through an investigation of the correlation between PROMIS and commonly used SF-36 measures.
MATERIALS AND METHODS

Study Design
This is a cross-sectional study of symptoms and function in HCT survivors.
Study Population
All surviving adult patients undergoing transplantation at the Fred Hutchinson Cancer Research Center in Seattle, Washington, are mailed annual surveys, regardless of their disease status. HCT recipients receive these surveys on approximately their transplant anniversaries and are sent 1 reminder if the survey is not returned within 1 month. Patients provide written informed consent at the time of their transplants, and only 3.7% of autologous recipients and 2.1% of allogeneic recipients decline, later stop participating, or are not allowed to be contacted (eg, because of incarceration). An online option that mirrors the paper version is available to all survey recipients. The annual survey consists of a core set of questions along with a modifiable research module that is distributed for 1 year. The July 2015 to June 2016 module included PROMIS measures and was mailed to a total of 4446 adults, including 93 whose family subsequently reported that the patient had died since last contact.
Measures
The SF-36 is a 36-item scale constructed to survey health status and quality of life. 18 It consists of 8 domains, which are the weighted sums of relevant questions. The items use Likert-type scales, some with 5 or 6 points and others with 2 or 3 points. Each scale of the 8 domains is transformed into a standardized, 0 to 100 z score (with a mean of 50 and a standard deviation of 10). Lower scores indicate worse symptoms and function. The 8 domains are Vitality, Physical Functioning, Bodily Pain, General Health, Role-Physical Functioning, Role-Emotional Functioning, Social Functioning, and Mental Health. Two composite scores can also be generated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS).
PROMIS consists of item banks with a variable number of questions that can be combined to form multiitem measures of varying length and complexity. 9 The items use Likert-type scales with 5 points. Because each item is mapped onto a common metric, measures of different lengths can be compared with one another. Similarly to the SF-36, PROMIS uses a T score-standardized metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation of that population. For negatively worded concepts such as fatigue, a higher T score represents greater fatigue, whereas for a positively worded concept such as physical function, a higher T score reflects higher (better) physical function. We used 2 PROMIS instruments. The Patient-Reported Outcomes Measurement Information System-Global Health (PROMIS-GH) scale (Global-10) is an instrument that consists of 10 items, and it can be scored into a global physical health component (Global Health-Physical [GH-Physical]) and a global mental health component (Global Health-Mental [GH-Mental]). Every question in a domain must be answered for that domain to be scored. PROMIS-GH is conceptually similar to the 12-Item Short Form Health Survey. 19 The 29-Item PatientReported Outcomes Measurement Information System Profile (PROMIS-29) contains 7 PROMIS domains with 4 questions each (short forms) and 1 pain intensity question. The PROMIS short forms in PROMIS-29 include the following: Depression (4a), Anxiety (4a), Physical Function (PF4a), Pain Interference (4a), Fatigue (4a), Sleep Disturbance (4a), and Ability to Participate in Social Roles and Activities (version 2; 4a).
Clinical Data
Clinical and sociodemographic variables were abstracted from each patient's chart in the institutional database.
These included age, sex, year of transplantation, conditioning intensity, donor type, cell source, and disease relapse. Patient self-report was used for posttransplant events, including GVHD and the comorbidity burden (pulmonary disease, avascular necrosis, adrenal insufficiency, and diabetes).
Ethical Permission
The study received ethical approval from the Fred Hutchinson Cancer Research Center's institutional review board, and all survey respondents provided signed informed consent.
Data Sharing
Our results provide benchmarks for PROMIS-29 and PROMIS-GH scores reported by long-term HCT survivors that can be referenced by future studies; scores for subsets are available from the authors.
Statistical Methods
Descriptive statistics for the population were calculated and compared between respondents and nonrespondents with the chi-square test and t test for categorical and continuous variables, respectively. Subsequent analyses were restricted to those who returned both a scorable SF-36 (>50% of the questions answered) and the PROMIS-GH measure (as a minimum). Because some patients did not answer every question in the PROMIS-GH instrument, there were very slight differences in the analytic populations. Cronbach's a was calculated for each PROMIS measure to evaluate internal consistency. 20 Differences between the SF-36 PCS and GH-Physical values and between the SF-36 MCS and GH-Mental values were compared with paired t tests. A P value < .01 was considered statistically different, and a difference of 5 points (half a standard deviation) was considered clinically meaningful. In addition, relations between global scores and domains across the SF-36 and PROMIS measures were examined with Pearson correlation coefficients. Cohen's criterion was used to interpret the magnitude of correlation coefficients (small, r < 0.3; medium, r 0.3 but <0.5; and large, r 0.5). 21 In addition, PROsetta Stone linkages were used to calculate PROMIS-29 measure scores from SF-36 raw scores (for physical function, pain, and vitality/fatigue), and extrapolated PROMIS-29 scores were then compared with the actual PROMIS-29 domain T scores with Pearson correlation coefficients.
Multivariate analyses were performed to investigate the relations between the composite scores for PROMIS-GH and SF-36 (physical and mental) and transplant-related factors (age, sex, year of transplantation, conditioning intensity, comorbidity burden, and relapse) in all recipients. In addition, the donor type, cell source, and chronic GVHD were considered in allogeneic recipients.
RESULTS
Both the SF-36 and PROMIS measures were available for 1634 HCT recipients (503 autologous recipients and 1131 allogeneic recipients), and an additional 382 (119 autologous recipients and 263 allogeneic recipients) had only 1 set of measures; the overall response rate was 46%. The median times since transplantation, at the time of the survey, for allogeneic and autologous recipients were 12.0 years (range, 0.4-44.1 years) and 6.1 years (range, 0.4-30.1 years), respectively. The larger numbers and longer survival for the allogeneic recipients reflect the early emphasis on allogeneic transplantation at the Fred Hutchinson Cancer Research Center. Tables 1 and 2 show the pretransplant characteristics for this study population as well as the differences between respondents and nonrespondents. Allogeneic nonrespondents were younger, were slightly longer out from transplantation, and were more likely to have received myeloablative conditioning, total body irradiation-based regimens, and bone marrow grafts than respondents. Autologous nonrespondents were younger and more likely to receive total body irradiation-based conditioning than respondents. Figure 1 shows the component score distributions for SF-36 (PCS and MCS) and PROMIS-GH (GH-Physical and GH-Mental) for allogeneic and autologous HCT recipients. For allogeneic patients (n 5 1131), the median SF-36 PCS score was 49.2 (interquartile range [IQR], , 23.9 to -3.1; P < .001) and -3.9 (95% CI, 24.4 to 23.3; P < .001) for the allogeneic and autologous recipients, respectively. Thus, the SF-36 PCS yields a statistically but not clinically meaningfully lower physical score than the PROMIS GH-Physical measure. The mean difference between the SF-36 MCS and GHMental scores in allogeneic and autologous recipients was 0.6 (95% CI, 0.1-1.0; P 5 .008) and 1.0 (95% CI, 0.3-1.6; P 5 .004), respectively, and this again was statistically different but not clinically meaningful. Figure 2A ,B shows the domain score distributions for the SF-36 and PROMIS-29 in allogeneic and autologous HCT recipients, respectively.
PRO Scores
Correlations Between the SF-36 and PROMIS Global-10 Measures (Table 4) . Using the functionality provided in PROsetta Stone, we found statistically significant correlations between the domain scores mapped from the SF-36 measures and the scores from the PROMIS measures as well as the SF-36 Mental Health scale and the PROMIS Anxiety and Depression scales (data not shown).
Association of Clinical Factors With Symptoms and Function
The results of the multivariate analyses are shown in Tables 5 and 6 . In allogeneic recipients, an older age at the time of the survey and less time since transplantation were associated with worse physical scores. Younger patients reported worse mental health as measured with the SF-36. When we considered posttransplant factors, a history of chronic GVHD and self-reported comorbidities were associated with significantly worse physical and mental functioning whether they were measured with PROMIS-GH or the SF-36 (although this was not statistically significant as measured with the SF-36 MCS for comorbidities). A history of relapse was not significantly associated with PROs in allogeneic recipients. In autologous recipients, younger patients reported worse mental health (this was statistically significant on the SF-36 only). An older age, a shorter time after transplantation, the presence of comorbidities, and relapse were all associated with statistically significantly lower scores on the SF-36 PCS. Although the associations with these factors were all directionally consistent when they were measured with PROMIS-GH, only comorbidities were statistically significant.
DISCUSSION
These data provide information about symptoms and function for a very large number of long-term HCT survivors who received allogeneic or autologous transplantation at a single transplant center. The scores show that the overall symptoms and function of those patients who responded to the survey were similar to those of the general population. They also show that PROs, as measured by PROMIS, are strongly correlated with those from a legacy measure, the SF-36, either by the scoring of the patient responses on the SF-36 or by linkage through PROsetta Stone. The internal reliability of the PROMIS measures is high. These finding support the proposal that the PROMIS measures are reliable and can be used as an alternative PRO measure in the setting of HCT. 8 Among respondents, physical health was found to be approximately half a standard deviation below the general population norm (it was slightly lower for autologous recipients than allogeneic recipients). This is consistent with the HCT literature, in which continued long-term (mild to moderate) impairment in physical function, with respect to comparison groups, is reported, even 5 to 10 years after HCT. 22 We found that post-HCT events had a significant association with symptoms and function. The presence of self-reported chronic conditions (at least one of pulmonary disease, avascular necrosis, adrenal insufficiency, diabetes, and chronic GVHD) 5, 23 was highly correlated with physical function, as previously reported. 22 The presence of relapse was associated with worse physical function in autologous patients but not in allogeneic patients. Because of the long time after transplantation, there may have been fewer allogeneic patients experiencing issues related to relapse at the time of self-report (in comparison with autologous patients), 5 whereas patients who had relapsed earlier may have been less likely to remain alive. Alternatively, ongoing treatment or maintenance therapy for relapse may have affected symptoms and function. Although there did appear to be a general tendency for the SF-36 PCS to produce scores that were lower than GH-Physical scores by 3 to 4 points, these composite scores were strongly correlated. Our ability to screen for impaired physical function with the short PROMIS-GH 10-item questionnaire would be beneficial in terms of reducing the respondent burden and thus potentially increasing retention and participation. The respondent burden remains a significant concern and potential barrier to PRO collection. A recent meta-analysis of 20 studies examining the impact of the respondent burden found a significant association between a lower response rate and a longer questionnaire (P .0001). 24 Wood et al 17 reported that in an early post-HCT cohort, the median time to complete the PROMIS-GH measure was 3 minutes (with an electronic PRO system), and this further supports this benefit. Only 2 previous studies investigated the PROMIS measures in HCT patients. Wood et al 17 administered PROMIS-GH to 32 HCT recipients at the baseline and then weekly until day 100 after HCT. Although the numbers were too low for robust conclusions to be drawn, they found that the PRO scores varied predictably over time, with changes in the physical scores mirroring symptoms. In addition, they reported correlations between post-HCT PROMIS-GH scores and pedometry data and found associations between fewer average daily steps and worse scores in all physical and social domains. 15 They did not include any other measures as comparators. A cross-sectional study of 136 HCT recipients 16 provided evidence that the PROMIS Cancer Fatigue Short Form was reliable and valid in this population in comparison with legacy measures, including the Vitality subscale of the SF-36 and the Fatigue Symptom Inventory. Scores on the PROMIS Cancer Fatigue Short Form were positively associated with fatigue severity and fatigue disruptiveness as measured by the Fatigue Symptom Inventory (P < .0001), and lower PROMIS scores were associated with higher Vitality scores as measured by the SF-36 (P < .0001).
The pattern for mental scores differed from the patterns for the physical domains in our study. The mean mental scores were near the population norms for all measures, with a tendency for the PROMIS-GH score to be slightly but statistically significantly lower than the SF-36 score. Multivariate analysis showed that fewer clinical and demographic factors were significantly associated with the mental scores, although, as with physical function, post-HCT events had a significant impact on mental scores in the allogeneic setting. In addition, younger patients reported worse mental functioning. These findings suggest that post-HCT survivors, particularly younger patients and those with ongoing clinical issues, should be regularly assessed for anxiety and depression with a low threshold for offering interventions. The general consistency in the direction of the effect of clinical predictors provides some indirect support for the comparability of the SF-36 and PROMIS-GH.
Our study has several limitations. First, fewer than half of the patients completed the PRO measures, and a small proportion returned only one or another of the measures; this precluded inclusion in the analysis. It is unlikely that a response bias resulting from these missing data would have affected conclusions about the correlation between the PROMIS and SF-36 measures; however, it is possible that the associations found in the multivariate analysis may not be generalizable because of demographic differences between those who did and did not return the PRO measures. Future interventions to encourage participation, particularly from underrepresented populations (eg, younger patients), are needed. Second, because it is cross-sectional, as in previous HCT publications, 16 the test-retest reliability and sensitivity to change of the PROMIS measures could not be assessed. Future longitudinal studies are necessary to confirm that the PROMIS measures perform as expected in the setting of long-term HCT survivorship. Third, the measures were delivered as static forms, and time studies to address the respondent burden were not performed specifically for the PROMIS forms. Future studies using CAT should be performed to understand the degree to which this approach decreases the respondent burden because there could be trade-offs in terms of ease of survey administration for staff. Finally, although the PROMIS measures have been extensively validated in general, their content validity and internal structure have not been specifically addressed in this population, and further research in this area is recommended.
In conclusion, we found that the PROMIS measures performed as expected when they were used alongside a well-understood legacy measure, the SF-36, in a crosssectional population of HCT recipients. In this setting, we believe that the short PROMIS-GH measure provides an attractive screening tool with the benefits in delivery, logistics, and cost that the PROMIS measures offer to reduce the respondent burden and enhance patient participation and retention.
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